1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 41

    Sharing and reusing data: toxicology assessment meta-analysis of various e-liquids and heat-not-burn platforms with INTERVALS datasets

    STAN A.; BOUÉ S.; HOENG J.; PEITSCH M.C.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Extensive scientific studies are conducted to assess the relative risks of various candidate modified risk tobacco products compared with those of smoking cigarettes. As the scientific community conducts such assessments for diverse products and in a...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 47

    Identification, discussion and recommendations for the optimal generation and use of in vitro genotoxicity assay data for tobacco and nicotine products

    DESAI P.(1); CURREN R.(1); MOORE M.M.(2)
    (1) Institute for In Vitro Sciences, Gaithersburg, MD, U.S.A.; (2) Ramboll Environ Inc., Little Rock, AR, U.S.A.
    The Institute for In Vitro Sciences is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific/technical approaches for utilizing in vitro regulatory genotoxicity assay data within and across tobacco...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 57

    Cross-cultural equivalence of the ABOUT™–Perceived Risk instrument in seven languages

    CHREA C.(1); CANO S.(2); SALZBERGER T.(3); MAINY N.(1); ACQUADRO C.(4); POPIELNICKI A.(5); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Modus Outcomes, Letchworth Garden City, U.K.; (3) University of Economics and Business, Vienna, Austria; (4) Mapi Research Trust, ICON plc, Lyon, France; (5) TransPerfect, Linguistic Validation Group, Boston, MA, U.S.A.
    The risk of smoking has long been well understood by consumers. However, it is important to measure the perceived risks by consumers of novel smoke-free alternatives to cigarettes. The ABOUT™–Perceived Risk instrument was developed to allow the...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 59

    A novel repository for consumer reported outcome measures in tobacco research: development, implementation and evolution from 2016 to date

    CLERC E.(1); MAINY N.(1); PERRET C.(2); ACQUADRO C.(3); BACSO A.(1); BINGGELI P.(1); CHREA C.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Mapi Research Trust, Lyon, France; (3) ICON plc, Lyon, France
    The consumer reported outcome measures Repository is a measurement instrument knowledge base developed by Mapi Research Trust (MRT) for Philip Morris International (PMI) in June 2016. It enables PMI researchers to identify and select measures to...
  8. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 008

    Workshop series to identify, discuss and develop recommendations for the optimal generation and use of in vitro genotoxicity assay data for tobacco and nicotine products

    MOORE M.M.(1); CURREN R.(2)
    (1) Ramboll US Corporation, Little Rock, AR, USA; (2) Institute for In Vitro Sciences, Gaithersburg, MD, USA
    The Institute for In Vitro Sciences is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific/technical approaches for utilizing in vitro regulatory genotoxicity assay data within and across tobacco...
  9. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 022 (also presented at CORESTA SSPT2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); HOENG J.(2); PEITSCH M.(2); SKOWRONEK A.(3); LEE K.M.(1)
    (1) Altria Client Services, Richmond, VA, USA; (2) Philip Morris International, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, USA
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  10. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 01

    Cross-sectional surveys on the use of tobacco products in the general population and in users of IQOS in Germany, Italy, and London (2018-2020): introducing the study protocols

    SPONSIELLO-WANG Z.; LANGER P.; PRIETO L.; DOBRYNINA M.; SKIADA D.; CAMILLE N.; WEITKUNAT R.; LÜDICKE F.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    Background: Philip Morris International (PMI) launched cross-sectional surveys in Italy, Germany, and London in March 2018 following the commercialization of a heat-not-burn tobacco product, IQOS. This publication introduces the study protocols....